nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
African self-sufficiency in cancer control
|
Tawfiles, Davidi |
|
|
26 |
7 |
p. e342 |
artikel |
2 |
Analysis of drug consumption and expenditure of WHO essential medicines for cancer in 40 countries and regions between 2012 and 2022: a multinational drug use study
|
Jiao, Yuanshi |
|
|
26 |
7 |
p. 877-886 |
artikel |
3 |
2025 ASCO Annual Meeting
|
Gourd, Katherine |
|
|
26 |
7 |
p. 841 |
artikel |
4 |
Benchmarking infrastructure for cancer control in Commonwealth countries: a population-based observational study
|
Reddy, Che L |
|
|
26 |
7 |
p. 924-935 |
artikel |
5 |
Bridging borders for resilience in cancer control in the Middle East: a strategic alliance of Saudi Arabia, Qatar, and Jordan
|
Jafar, Hanan |
|
|
26 |
7 |
p. e390-e397 |
artikel |
6 |
Bridging borders in cancer control
|
Kutluk, Tezer |
|
|
26 |
7 |
p. 835-836 |
artikel |
7 |
Bridging tumour classification and treatment
|
Subbiah, Vivek |
|
|
26 |
7 |
p. e343-e344 |
artikel |
8 |
Cabozantinib plus atezolizumab in metastatic prostate cancer (CONTACT-02): final analyses from a phase 3, open-label, randomised trial
|
Agarwal, Neeraj |
|
|
26 |
7 |
p. 860-876 |
artikel |
9 |
Cancer care in Bahrain: progress, challenges, and strategic priorities
|
Hamadeh, Randah R |
|
|
26 |
7 |
p. 830-831 |
artikel |
10 |
Cancer control in the Middle East
|
Prowse, Jamie |
|
|
26 |
7 |
p. 829-830 |
artikel |
11 |
Cancer control in the Middle East: Kuwait perspective
|
Al-Naaimi, Meshari |
|
|
26 |
7 |
p. 832-833 |
artikel |
12 |
Cancer control in the United Arab Emirates
|
Mukherji, Deborah |
|
|
26 |
7 |
p. e381-e389 |
artikel |
13 |
Cancer took centre stage at the World Health Assembly
|
Adepoju, Paul |
|
|
26 |
7 |
p. 839 |
artikel |
14 |
Considerations for results of the patient-reported outcome analyses of the TALAPRO-2 trial
|
de Boissieu, Paul |
|
|
26 |
7 |
p. e345 |
artikel |
15 |
CONTACT-02 and beyond: rethinking immunotherapy strategies in metastatic prostate cancer
|
Mukherji, Deborah |
|
|
26 |
7 |
p. 819-821 |
artikel |
16 |
Correction to Lancet Oncol 2024; 25: 1614–24
|
|
|
|
26 |
7 |
p. e349 |
artikel |
17 |
Correction to Lancet Oncol 2025; 26: 503–15
|
|
|
|
26 |
7 |
p. e349 |
artikel |
18 |
Correction to Lancet Oncol 2025; 26: 571–82
|
|
|
|
26 |
7 |
p. e349 |
artikel |
19 |
Correction to Lancet Oncol 2025; 26: 924–35
|
|
|
|
26 |
7 |
p. e349 |
artikel |
20 |
Correction to Lancet Oncol 2025; 26: e46–54
|
|
|
|
26 |
7 |
p. e349 |
artikel |
21 |
Correction to Lancet Oncol 2025; 26: e320–30
|
|
|
|
26 |
7 |
p. e349 |
artikel |
22 |
Demystifying the WHO Model Lists of Essential Medicines for cancer care
|
Trapani, Dario |
|
|
26 |
7 |
p. 821-823 |
artikel |
23 |
England changes cervical cancer screening to every 5 years
|
Kirby, Tony |
|
|
26 |
7 |
p. e350 |
artikel |
24 |
Equity in cancer genomics in the UK: a cross-sectional analysis of a national cancer cohort
|
Nguyen, T |
|
|
26 |
7 |
p. 971-980 |
artikel |
25 |
First-in-world “Trojan horse” drug offered to multiple myeloma patients in England
|
Burki, Talha |
|
|
26 |
7 |
p. e351 |
artikel |
26 |
From conflict to care: rebuilding Syria's oncology infrastructure
|
Tawfiles, Davidi |
|
|
26 |
7 |
p. 833-835 |
artikel |
27 |
Health-related quality of life, pain, and symptomatic skeletal events with [177Lu]Lu-PSMA-617 in patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): an open-label, randomised, phase 3 trial
|
Fizazi, Karim |
|
|
26 |
7 |
p. 948-959 |
artikel |
28 |
Hormonal therapy for young-onset breast cancer: current understanding and lessons
|
Lévy, Christelle |
|
|
26 |
7 |
p. 824-825 |
artikel |
29 |
Hormone therapy use and young-onset breast cancer: a pooled analysis of prospective cohorts included in the Premenopausal Breast Cancer Collaborative Group
|
O’Brien, Katie M |
|
|
26 |
7 |
p. 911-923 |
artikel |
30 |
Improved recruitment equity in a UK cancer genomic testing programme
|
Evans, D Gareth |
|
|
26 |
7 |
p. 827-829 |
artikel |
31 |
Intensity-modulated moderately hypofractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-C): early toxicity results from a randomised, open-label, phase 3, non-inferiority trial
|
Tree, Alison C |
|
|
26 |
7 |
p. 936-947 |
artikel |
32 |
Millions could lose Medicaid coverage under US budget bill
|
Devi, Sharmila |
|
|
26 |
7 |
p. 838 |
artikel |
33 |
Overall efficacy and safety of olanzapine 5 mg added to triplet antiemetics for an anthracycline-containing regimen in patients with breast cancer: a phase 3, double-blind, randomised, placebo-controlled trial
|
Saito, Mitsue |
|
|
26 |
7 |
p. 960-970 |
artikel |
34 |
Overall survival in patients with hormone receptor-positive, HER2-negative advanced breast cancer treated in a phase 1b trial evaluating gedatolisib in combination with palbociclib and endocrine therapy
|
Layman, Rachel M |
|
|
26 |
7 |
p. e332-e333 |
artikel |
35 |
Partial-breast irradiation: has the dust finally settled?
|
Krug, David |
|
|
26 |
7 |
p. 823-824 |
artikel |
36 |
Partial-breast radiotherapy after breast conservation surgery for women with early breast cancer (UK IMPORT LOW): 10-year outcomes from a multicentre, open-label, randomised, controlled, phase 3, non-inferiority trial
|
Kirby, Anna M |
|
|
26 |
7 |
p. 898-910 |
artikel |
37 |
Politics and pharma: hurdles in UK science ambitions
|
The Lancet Oncology, |
|
|
26 |
7 |
p. 817 |
artikel |
38 |
Practice standard in British Colombia impacting opioid prescriptions for people with cancer
|
Burki, Talha |
|
|
26 |
7 |
p. 837 |
artikel |
39 |
Qatar national cancer care and research: pioneering strategies for global health excellence
|
Al-Thani, Mohammed Bin Hamed |
|
|
26 |
7 |
p. e369-e380 |
artikel |
40 |
RADIOSA and the management of oligorecurrent prostate cancer: a step forward, but the journey continues
|
Vis, André N |
|
|
26 |
7 |
p. e334 |
artikel |
41 |
RADIOSA and the management of oligorecurrent prostate cancer: a step forward, but the journey continues
|
Aluwini, Shafak |
|
|
26 |
7 |
p. e335 |
artikel |
42 |
Real-world challenges and considerations in treating von Hippel-Lindau disease with HIF-2α inhibitors
|
de Velasco, Guillermo |
|
|
26 |
7 |
p. e346 |
artikel |
43 |
Real-world challenges and considerations in treating von Hippel-Lindau disease with HIF-2α inhibitors
|
Larcher, Alessandro |
|
|
26 |
7 |
p. e347 |
artikel |
44 |
Real-world challenges and considerations in treating von Hippel-Lindau disease with HIF-2α inhibitors – Authors' reply
|
Srinivasan, Ramaprasad |
|
|
26 |
7 |
p. e348 |
artikel |
45 |
Rwanda provides free treatment to all cancer patients
|
Nakkazi, Esther |
|
|
26 |
7 |
p. 840 |
artikel |
46 |
SANO trial: innovations, risks, and unanswered questions
|
Kapoor, Akhil |
|
|
26 |
7 |
p. e336 |
artikel |
47 |
SANO trial: innovations, risks, and unanswered questions
|
Markar, Sheraz R |
|
|
26 |
7 |
p. e338 |
artikel |
48 |
SANO trial: innovations, risks, and unanswered questions
|
Housman, Brian |
|
|
26 |
7 |
p. e337 |
artikel |
49 |
SANO trial: innovations, risks, and unanswered questions
|
Oruç, Ahmet |
|
|
26 |
7 |
p. e339 |
artikel |
50 |
SANO trial: innovations, risks, and unanswered questions – Authors' reply
|
van der Wilk, Berend J |
|
|
26 |
7 |
p. e340-e341 |
artikel |
51 |
Setting the PACE for prostate radiotherapy
|
Nickols, Nicholas G |
|
|
26 |
7 |
p. 826-827 |
artikel |
52 |
Solutions for tackling the global surgery crisis in west Africa
|
Cheng, Leo |
|
|
26 |
7 |
p. 843-845 |
artikel |
53 |
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trial
|
Zhou, Caicun |
|
|
26 |
7 |
p. 887-897 |
artikel |
54 |
The CANDLE mission begins in EU countries
|
Das, Manjulika |
|
|
26 |
7 |
p. 842 |
artikel |
55 |
Towards a comprehensive cancer control policy in Saudi Arabia
|
Alessy, Saleh A |
|
|
26 |
7 |
p. e360-e368 |
artikel |
56 |
Transforming cancer care in Jordan: a 10-year comprehensive patient-centred strategy guided by local experts
|
Abdel-Razeq, Hikmat |
|
|
26 |
7 |
p. e352-e359 |
artikel |
57 |
You are her son, not her doctor
|
Eyrich, Nicholas W |
|
|
26 |
7 |
p. 846 |
artikel |
58 |
Zanidatamab, a bispecific monoclonal antibody for HER2-positive gastro-oesophageal adenocarcinoma patients: a new hope?
|
Coutzac, Clélia |
|
|
26 |
7 |
p. 818-819 |
artikel |
59 |
Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study
|
Elimova, Elena |
|
|
26 |
7 |
p. 847-859 |
artikel |